DSM-Firmenich AG (DSFIY)
Market Cap | 26.48B |
Revenue (ttm) | 13.25B |
Net Income (ttm) | 258.83M |
Shares Out | n/a |
EPS (ttm) | 0.97 |
PE Ratio | 102.30 |
Forward PE | n/a |
Dividend | 0.22 (2.27%) |
Ex-Dividend Date | May 9, 2024 |
Volume | 191,100 |
Average Volume | 67,369 |
Open | 9.91 |
Previous Close | 9.68 |
Day's Range | 9.77 - 10.01 |
52-Week Range | 9.48 - 13.98 |
Beta | n/a |
RSI | 43.40 |
Earnings Date | Jul 31, 2025 |
About DSM-Firmenich AG
DSM-Firmenich AG engages in the provision of solutions for nutrition, health, and beauty businesses in the Switzerland, Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, includin... [Read more]
Financial Performance
In 2024, DSM-Firmenich AG's revenue was 12.80 billion, an increase of 20.44% compared to the previous year's 10.63 billion. Earnings were 250.00 million, a decrease of -88.27%.
Financial numbers in EUR Financial StatementsNews

Human Milk Oligosaccharides (HMOs) Market Insights 2025, Analysis and Forecast to 2030 Featuring Key Companies - DSM-Firmenich, Kyowa Hakko, and Chr. Hansen
Dublin, March 26, 2025 (GLOBE NEWSWIRE) -- The "Human Milk Oligosaccharides (HMOs) Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Produ...

dsm-firmenich showcases integrated approach to sustainability and business performance at Sustainability Investor Day
Press Release dsm-firmenich showcases integrated approach to sustainability and business performance at Sustainability Investor Day Kaiseraugst (Switzerland), Maastricht (Netherlands), March 25, 2025 ...

DSM-Firmenich: Improving Fundamentals At A More Digestible Valuation
DSM-Firmenich's FY 2024 results show promising growth and profitability, with 6% organic sales growth and 19% adjusted EBITDA increase, despite a challenging macroeconomic environment. The company is ...

dsm-firmenich publishes 2024 Integrated Annual Report
Press Release dsm-firmenich publishes 2024 Integrated Annual Report Kaiseraugst (Switzerland), Maastricht (Netherlands), February 28, 2025 dsm-firmenich today announces the publication of its 2024 Int...

dsm-firmenich issues €750 million long-term bond
Press Release dsm-firmenich issues €750 million long-term bond Kaiseraugst (Switzerland), Maastricht (Netherlands), February 19, 2025 dsm-firmenich today announces the successful launch of a €750 mill...
DSM-Firmenich is a smarter, faster working engine post merger, says CEO
Dimitri De Vreeze, CEO of Dsm-Firmenich, talks about the company's merger and share buyback program off the back of its full-year earning results.

DSM-Firmenich AG (KDSKF) Q3 2024 Earnings Call Transcript
DSM-Firmenich AG (OTC:KDSKF) Q3 2024 Earnings Conference Call October 31, 2024 4:00 AM ET Company Participants Dave Huizing - Head of Investor Relations Dimitri de Vreeze - Chief Executive Officer Ral...

dsm-firmenich to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on September 25 2024
Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event Company invites individual and institutional investors, as well as advisors,...

DSM-Firmenich AG (KDSKF) Q2 2024 Earnings Call Transcript
DSM-Firmenich AG (OTC:KDSKF) Q2 2024 Earnings Conference Call July 30, 2024 3:00 AM ET Company Participants Dave Huizing - Head of Investor Relations Dimitri de Vreeze - Chief Executive Officer Ralf S...

DSM-Firmenich AG (KDSKF) Q1 2024 Earnings Call Transcript
DSM-Firmenich AG (OTC:KDSKF) Q1 2024 Earnings Conference Call May 2, 2024 3:00 AM ET Company Participants Dave Huizing - Head of Investor Relations Ralf Schmeitz - Chief Financial Officer Conference C...